Lorenzo Turelli | Postdoctoral Researcher
University of Strasbourg
Lorenzo Turelli is a Postdoctoral researcher within the CBST unit of the University of Strasbourg, carrying out the scientific activity on the development of a novel format of Antibody-Drug Conjugates (ADCs). His research in chemical biology focus on the development of novel linker modalities for ADCs applications through organic synthesis and bioconjugation. He obtained his PhD at the University of Strasbourg in the frame of a Marie sklodowska-Curie project, within the Targeted-Anticancer Therapies (TACT) European consortium.
Appearances:
Festival of Biologics Day 2 @ 17:50
A novel linkerless ADCs platform for the production of new Auristatine-based drugs
The field of Antibody-Drug Conjugates (ADCs) has been flourishing for the last two decades, with increasing investments and a surging role in anticancer treatments. At the same time, research in the field has been aimed at enhancing their therapeutic windows, by controlling the effective delivery of the cytotoxic drug. However, despite the thriving innovations, the ADC technology has remained mostly unchanged since its introduction, always being based on the same model – a mAb, a linker (preferentially cleavable), and a highly potent drug – and following central dogmas built through the years. Reflecting on these points, we here introduce a new format of ADC, a linker-less one, obtained by turning the bioconjugation reaction into a synthetic step for the one-pot generation of a cytotoxic compound directly on the monoclonal antibody starting from two non-toxic fragments.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events